Myeloid Leukemia is a type of cancer that starts in the bone marrow. It happens when the body makes too many myeloid cells, which are a type of white blood cell. These extra cells crowd out healthy blood cells, making it hard for the body to fight infections and carry oxygen. This specific type affects the myeloid lineage, which includes granulocytes and monocytes.
Every report comes from a Lived member, sent anonymously.
Have you had Stem Cell Transplant for Myeloid Leukemia?
Myeloid leukemia is a group of blood cancers that start in the bone marrow, in the myeloid cells that normally mature into red blood cells, platelets and several kinds of infection-fighting white blood cells. A change in the DNA of one of these cells lets abnormal, immature cells called blasts multiply. As they build up, they crowd out the healthy cells the marrow should be making. That is why the disease so often shows up as tiredness from anemia (too few red blood cells), infections that are frequent or slow to clear, and easy bruising or bleeding. The name covers two very different diseases. Acute myeloid leukemia (AML) grows quickly and usually gets worse fast without treatment; it is the most common acute leukemia in adults. Chronic myeloid leukemia (CML) develops slowly, may cause no symptoms at first and is often found on a routine blood test. Which type someone has matters more than the shared label, because testing, treatment and outlook differ sharply between them.
Myeloid leukemia comes from genetic changes that a bone marrow cell acquires during a person's life. In most cases no one can say why the change happened, and having it does not mean a person did something to cause it. For AML, known risk factors include older age, being male, smoking, earlier chemotherapy or radiation therapy for another cancer, exposure to high levels of radiation or to the industrial chemical benzene, and a prior blood disorder such as myelodysplastic syndrome (a condition in which the marrow makes poorly formed blood cells). Some inherited syndromes also raise risk. Having a risk factor does not mean someone will develop AML, and many people who do have no known risk factor. Most people with CML have a chromosome change called the Philadelphia chromosome, in which pieces of chromosomes 9 and 22 trade places and join two genes into one, called BCR::ABL1. The fused gene makes an overactive protein that drives the marrow to produce too many white blood cells. This change arises in the marrow during life; it is not inherited and is not passed to children. Older age and high-dose radiation exposure are the main known risk factors.
Myeloid leukemia is often first suspected from a complete blood count (CBC), a routine test that counts red blood cells, white blood cells and platelets. In AML, red cells and platelets are often low, and white cells may be high or low. In CML, the white cell count is often very high. A blood smear, in which cells are examined under a microscope, can show blasts. Confirming the diagnosis usually requires a bone marrow aspiration and biopsy: after the skin is numbed, a hollow needle removes a small sample of marrow and bone, usually from the hip. The share of cells that are blasts helps define the disease. AML is generally diagnosed when at least 20% of the marrow cells are blasts or certain defining gene changes are present. In CML, the blast share sets the phase: under 10% is chronic phase, when most people are diagnosed; 10% to 19% is accelerated phase; and 20% or more is blast phase, which behaves like an acute leukemia. Chromosome and gene tests on the blood or marrow are a central part of the workup. They confirm the Philadelphia chromosome in CML, identify AML subtypes such as acute promyelocytic leukemia, and find changes, such as a FLT3 gene mutation, that point to specific targeted drugs. A lumbar puncture (spinal tap) or imaging is sometimes added to check whether leukemia cells have spread beyond the blood and marrow.
AML needs treatment right away. For people well enough to receive it, treatment usually begins with intensive chemotherapy in the hospital, built around the drug cytarabine combined with another such as daunorubicin. This first phase, called induction, aims for remission: normal blood counts, fewer than 5% blasts in the marrow and no other sign of leukemia. A second phase, consolidation, follows to destroy remaining leukemia cells that could otherwise regrow. For some people, consolidation includes a stem cell transplant from a donor, an intensive procedure that can lower the chance of relapse but carries significant risks of its own, so it is weighed against each person's genetic results and overall health. Targeted drugs are added when tests find a matching change, such as midostaurin or quizartinib for AML with a FLT3 mutation. Many people with AML are older or have other health problems that make intensive chemotherapy too risky. A lower-intensity approach combines venetoclax (Venclexta), a targeted pill, with azacitidine or decitabine (chemotherapy drugs given in repeated cycles) or with low-dose cytarabine, and it continues as long as it is helping. Other targeted pills may be used when specific gene changes are found. Acute promyelocytic leukemia, a subtype of AML, can cause severe bleeding and blood clots, so it needs treatment as soon as it is suspected. It is treated differently from other AML, mainly with all-trans retinoic acid (ATRA, a vitamin A-related drug) and arsenic trioxide, which push the leukemia cells to mature or die. CML is usually treated with a tyrosine kinase inhibitor (TKI), a daily pill that blocks the overactive protein made by BCR::ABL1. Imatinib (Gleevec, also sold as a generic) was the first; dasatinib, nilotinib, bosutinib and asciminib are alternatives, chosen by side effects, other health conditions and how well the leukemia responds. Stem cell transplant is an option mainly for CML that reaches an advanced phase or does not respond to TKIs. With either type, supportive care is part of treatment: red blood cell and platelet transfusions, and antibiotics or antifungal medicines to prevent or treat infection while blood counts are low. Clinical trials are a reasonable option to ask about, particularly for AML.
AML treatment is most intense at the start. Induction chemotherapy usually means a hospital stay while blood counts drop and then recover, with transfusions and close watching for infection. The outlook varies widely with age, the leukemia's genetic features and overall health, and older age is linked to lower remission rates and more complications. Across all ages in the United States, about one in three people with AML are alive five years after diagnosis, and the median age at diagnosis is 70. Because AML can return after remission, blood tests and sometimes marrow tests continue after treatment ends. CML in chronic phase is usually a long-term condition managed with pills taken at home. With modern TKIs, most people diagnosed in chronic phase have a normal or near-normal life expectancy. Regular blood tests measure the amount of BCR::ABL1 with a sensitive test called quantitative PCR, and results are compared with expected milestones. If levels do not fall enough, or side effects cannot be made tolerable, switching to another TKI is the usual next step. Some people whose BCR::ABL1 level stays extremely low for a long time can stop treatment under close monitoring, called treatment-free remission, and restart if the level rises. For both types, treatment brings frequent appointments and periods of low blood counts, so planning for time off work, transportation and help at home is often part of the first months.
See a clinician if you have ongoing tiredness, unexplained weight loss, drenching night sweats, frequent or lingering infections, easy bruising or tiny red dots under the skin, or fullness or pain under the left ribs, which can signal an enlarged spleen. A complete blood count is a simple first test. During treatment, call the care team right away, at any hour, for a fever of 100.5°F (38°C) or higher or for chills, because infections can become life threatening quickly when white blood cells are low. Check with the team before taking anything to bring a fever down, since that can hide an infection. Also call right away for bleeding that does not stop after a few minutes, black or bloody stools, red or pink urine, or a bad headache, vision changes, confusion or unusual sleepiness.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Myeloid Leukemia is like, what's helped you, or ask the community a question.